Table 3.
Cumulative patterns of progression following all therapy.
| PCI Not Received (N=44) |
PCI Received (N=41) |
p value | |
|---|---|---|---|
| No. of sites | 0.1278 | ||
| Median | 2 | 2 | |
| Range | (0–8) | (0–5) | |
| No. of sites | 0.2575 | ||
| 0 | 3 (6.8%) | 4 (9.7%) | |
| 1–2 | 26 (59.1%) | 17 (41.5%) | |
| 3–8 | 15 (34.1%) | 20 (48.8%) | |
| Sites of Progression | |||
| Hilar nodes | 13 (29.5%) | 21 (51.2%) | 0.0489 |
| Mediastinal nodes | 13 (29.5%) | 16 (39.0%) | 0.3716 |
| Supraclavicular/scalene nodes | 6 (13.6%) | 5 (12.2%) | 1.0000 |
| Primary lung | 13 (29.5%) | 25 (61.0%) | 0.0047 |
| Contralateral lung | 3 (6.8%) | 1 (2.4%) | 0.6169 |
| Pleura | 2 (4.5%) | 4 (9.8%) | 0.4227 |
| Liver | 14 (32.6%) | 9 (21.4%) | 0.3383 |
| Adrenals | 4 (9.1%) | 4 (9.8%) | 1.0000 |
| Bone | 3 (6.8%) | 5 (12.2%) | 0.4738 |
| Bone marrow | 0 | 0 | -- |
| CNS-brain | 12 (27.3%) | 5 (12.2%) | 0.1065 |
| Skin | 0 | 0 | -- |
| Other nodal | 13 (29.5%) | 10 (24.4%) | 0.6326 |
| Other sites | 6 (13.6%) | 6 (14.6%) | 1.0000 |
PCI, prophylactic cranial irradiation; CNS, central nervous system